Literature DB >> 10878335

The abrogation of allosensitization following the induction of mixed allogeneic chimerism.

Y L Colson1, M J Schuchert, S T Ildstad.   

Abstract

The association of preformed anti-donor Abs with the hyperacute rejection of bone marrow and solid organ allografts and the persistence of the anti-donor immune response secondary to immunologic memory make allosensitization an absolute contraindication to transplantation. Mixed allogeneic (A + B-->A) bone marrow chimerism has been demonstrated to confer donor-specific tolerance in nonsensitized recipients, but has not been evaluated in the setting of allosensitization. The current study documents that despite significant anti-donor sensitization, mixed allogeneic engraftment is possible and provides a marked advantage over fully allogeneic (B-->A) models. Moreover, the acceptance of donor skin grafts and loss of circulating anti-donor Abs suggest that allosensitization can be abrogated with the induction of stable mixed allogeneic chimerism.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10878335     DOI: 10.4049/jimmunol.165.2.637

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  7 in total

1.  Sensitization to minor antigens is a significant barrier in bone marrow transplantation and is prevented by CD154:CD40 blockade.

Authors:  H Xu; Y Huang; L R Hussain; Z Zhu; L D Bozulic; C Ding; J Yan; S T Ildstad
Journal:  Am J Transplant       Date:  2010-07       Impact factor: 8.086

2.  Humoral immunity is the dominant barrier for allogeneic bone marrow engraftment in sensitized recipients.

Authors:  Hong Xu; Paula M Chilton; Michael K Tanner; Yiming Huang; Carrie L Schanie; Mariano Dy-Liacco; Jun Yan; Suzanne T Ildstad
Journal:  Blood       Date:  2006-08-03       Impact factor: 22.113

3.  Preformed antibody, not primed T cells, is the initial and major barrier to bone marrow engraftment in allosensitized recipients.

Authors:  Patricia A Taylor; Michael J Ehrhardt; Matthew M Roforth; Jessica M Swedin; Angela Panoskaltsis-Mortari; Jonathan S Serody; Bruce R Blazar
Journal:  Blood       Date:  2006-10-03       Impact factor: 22.113

4.  Costimulatory blockade of CD154-CD40 in combination with T-cell lymphodepletion results in prevention of allogeneic sensitization.

Authors:  Hong Xu; Jun Yan; Yiming Huang; Paula M Chilton; Chuanlin Ding; Carrie L Schanie; Li Wang; Suzanne T Ildstad
Journal:  Blood       Date:  2007-09-07       Impact factor: 22.113

5.  Syngeneic transplantation of hematopoietic stem cells that are genetically modified to express factor VIII in platelets restores hemostasis to hemophilia A mice with preexisting FVIII immunity.

Authors:  Qizhen Shi; Scot A Fahs; David A Wilcox; Erin L Kuether; Patricia A Morateck; Nicole Mareno; Hartmut Weiler; Robert R Montgomery
Journal:  Blood       Date:  2008-05-21       Impact factor: 22.113

6.  The Presence of Anti-HLA Antibodies before and after Allogeneic Hematopoietic Stem Cells Transplantation from HLA-Mismatched Unrelated Donors.

Authors:  Anna Koclega; Miroslaw Markiewicz; Urszula Siekiera; Alicja Dobrowolska; Mizia Sylwia; Monika Dzierzak-Mietla; Patrycja Zielinska; Malgorzata Sobczyk Kruszelnicka; Andrzej Lange; Slawomira Kyrcz-Krzemien
Journal:  Bone Marrow Res       Date:  2012-10-24

7.  Desensitization using imlifidase and EndoS enables chimerism induction in allosensitized recipient mice.

Authors:  Jiaxin Lin; Louis Boon; Robert Bockermann; Anna-Karin Robertson; Christian Kjellman; Colin C Anderson
Journal:  Am J Transplant       Date:  2020-04-07       Impact factor: 8.086

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.